Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Primary Purpose
COPD
Status
Completed
Phase
Phase 3
Locations
Korea, Republic of
Study Type
Interventional
Intervention
aclidinium bromide 400 μg
aclidinium bromide placebo
Sponsored by
About this trial
This is an interventional trial for COPD
Eligibility Criteria
Inclusion Criteria:
- A diagnosis of stable moderate to severe COPD as defined by GOLD (the Global Initiative for Chronic Obstructive Lung Disease) guidelines(http://www.goldcopd.org); a postbronchodilator FEV1/forced vital capacity [FVC] ratio < 70% and FEV1 ≥ 30% to <80% of the predicted value.
- Current or former cigarette smokers with a smoking history of at least 10 pack-years.
Exclusion Criteria:
- History or current diagnosis of asthma
- Patients who have been hospitalized for an acute COPD exacerbation within 3 months prior to Visit 1
- Any respiratory tract infection (including the upper respiratory tract) or COPD exacerbation in the 6 weeks before Visit 1.
- Patients with any clinically significant respiratory conditions other than COPD
Sites / Locations
- Seoul National University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
aclidinium bromide
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Change from baseline to Week 12 in morning predose (trough) FEV1
Secondary Outcome Measures
Change from baseline to Week 12 in peak FEV1
Full Information
NCT ID
NCT01636401
First Posted
July 6, 2012
Last Updated
August 20, 2013
Sponsor
Daewoong Pharmaceutical Co. LTD.
1. Study Identification
Unique Protocol Identification Number
NCT01636401
Brief Title
Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Official Title
Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Study Type
Interventional
2. Study Status
Record Verification Date
August 2013
Overall Recruitment Status
Completed
Study Start Date
August 2012 (undefined)
Primary Completion Date
May 2013 (Actual)
Study Completion Date
May 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Daewoong Pharmaceutical Co. LTD.
4. Oversight
5. Study Description
Brief Summary
The purpose of this study was to observe the Efficacy and safety of 400 μg twice daily of aclidinium bromide vs. placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COPD
7. Study Design
Study Phase
Phase 3
8. Arms, Groups, and Interventions
Arm Title
aclidinium bromide
Arm Type
Active Comparator
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
aclidinium bromide 400 μg
Intervention Type
Drug
Intervention Name(s)
aclidinium bromide placebo
Primary Outcome Measure Information:
Title
Change from baseline to Week 12 in morning predose (trough) FEV1
Time Frame
Week 12
Secondary Outcome Measure Information:
Title
Change from baseline to Week 12 in peak FEV1
Time Frame
Week 12
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
A diagnosis of stable moderate to severe COPD as defined by GOLD (the Global Initiative for Chronic Obstructive Lung Disease) guidelines(http://www.goldcopd.org); a postbronchodilator FEV1/forced vital capacity [FVC] ratio < 70% and FEV1 ≥ 30% to <80% of the predicted value.
Current or former cigarette smokers with a smoking history of at least 10 pack-years.
Exclusion Criteria:
History or current diagnosis of asthma
Patients who have been hospitalized for an acute COPD exacerbation within 3 months prior to Visit 1
Any respiratory tract infection (including the upper respiratory tract) or COPD exacerbation in the 6 weeks before Visit 1.
Patients with any clinically significant respiratory conditions other than COPD
Facility Information:
Facility Name
Seoul National University Hospital
City
Seoul
Country
Korea, Republic of
12. IPD Sharing Statement
Citations:
PubMed Identifier
26370136
Citation
Lee SH, Lee J, Yoo KH, Uh ST, Park MJ, Lee SY, Kim JY, Kim DK, Kim SJ, Lee KH, Yoo CG. Efficacy and safety of aclidinium bromide in patients with COPD: A phase 3 randomized clinical trial in a Korean population. Respirology. 2015 Nov;20(8):1222-8. doi: 10.1111/resp.12641. Epub 2015 Sep 15.
Results Reference
derived
Learn more about this trial
Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
We'll reach out to this number within 24 hrs